7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Schaaf‐Yang syndrome overview: Report of 78 individuals

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Schaaf‐Yang Syndrome (SYS) is a genetic disorder caused by truncating pathogenic variants in the paternal allele of the maternally imprinted, paternally expressed gene MAGEL2, located in the Prader‐Willi critical region 15q11‐15q13. SYS is a neurodevelopmental disorder that has clinical overlap with Prader‐Willi Syndrome in the initial stages of life but becomes increasingly distinct throughout childhood and adolescence. Here, we describe the phenotype of an international cohort of 78 patients with nonsense or frameshift mutations in MAGEL2. This cohort includes 43 individuals that have been reported previously, as well as 35 newly identified individuals with confirmed pathogenic genetic variants. We emphasize that intellectual disability/developmental delay, autism spectrum disorder, neonatal hypotonia, infantile feeding problems, and distal joint contractures are the most consistently shared features of patients with SYS. Our results also indicate that there is a marked prevalence of infantile respiratory distress, gastroesophageal reflux, chronic constipation, skeletal abnormalities, sleep apnea, and temperature instability. While there are many shared features, patients with SYS are characterized by a wide phenotypic spectrum, including a variable degree of intellectual disability, language development, and motor milestones. Our results indicate that the variation in phenotypic severity may depend on the specific location of the truncating mutation, suggestive of a genotype–phenotype association. This evidence may be useful in both prenatal and pediatric genetic counseling.

          Related collections

          Most cited references23

          • Record: found
          • Abstract: found
          • Article: not found

          The changing purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria.

          Prader-Willi syndrome (PWS) is a complex, multisystem disorder. Its major clinical features include neonatal hypotonia, developmental delay, short stature, behavioral abnormalities, childhood-onset obesity, hypothalamic hypogonadism, and characteristic appearance. The genetic basis of PWS is also complex. It is caused by absence of expression of the paternally active genes in the PWS critical region on 15q11-q13. In approximately 70% of cases this is the result of deletion of this region from the paternal chromosome 15. In approximately 28%, it is attributable to maternal uniparental disomy (UPD; inheritance of 2 copies of a chromosome from the mother and no copies from the father, as opposed to the normal 1 copy from each parent) of chromosome 15, and in 97% of the patients. Feeding problems in infancy, excessive weight gain after 1 year, hypogonadism, and hyperphagia were all present in 93% or more of patients. Sensitivities of the minor criteria ranged form 37% (sleep disturbance and apneas) to 93% (speech and articulation defects). Interestingly, the sensitivities of 8 of the minor criteria were higher than the sensitivity of characteristic facial features, which is a major criterion. Fifteen out of 90 patients with molecular diagnosis did not meet the clinical diagnostic criteria retrospectively. When definitive diagnostic testing is not available, as was the case for PWS when the 1993 criteria were developed, diagnostic criteria are important to avoid overdiagnosis and to ensure that diagnostic test development is performed on appropriate samples. When diagnostic testing is available, as is now the case for PWS, diagnostic criteria should serve to raise diagnostic suspicion, ensure that all appropriate people are tested, and avoid the expense of testing unnecessarily. Our results indicate that the sensitivities of most of the published criteria are acceptable. However, 16.7% of patients with molecular diagnosis did not meet the 1993 clinical diagnostic criteria retrospectively, suggesting that the published criteria may be too exclusive. A less strict scoring system may ensure that all appropriate people are tested. Accordingly, we suggest revised clinical criteria to help identify the appropriate patients for DNA testing for PWS. The suggested age groupings are based on characteristic phases of the natural history of PWS. Some of the features (eg, neonatal hypotonia, feeding problems in infancy) serve to diagnose the syndrome in the first few years of life, whereas others (eg, excessive eating) are useful during early childhood. Similarly, hypogonadism is most useful during and after adolescence. Some of the features like neonatal hypotonia and infantile feeding problems are less likely to be missed, whereas others such as characteristic facial features and hypogonadism (especially in prepubertal females) may require more careful and/or expert examination. The issue of who should have diagnostic testing is distinct from the determination of features among confirmed patients. Based on the sensitivities of the published criteria and our experience, we suggest testing all newborns/infants with otherwise unexplained hypotonia with poor suck. For children between 2 and 6 years of age, we consider hypotonia with history of poor suck associated with global developmental delay sufficient criteria to prompt testing. Between 6 and 12 years of age, we suggest testing those with hypotonia (or history of hypotonia with poor suck), global developmental delay, and excessive eating with central obesity (if uncontrolled). At the ages of 13 years and above, we recommend testing patients with cognitive impairment, excessive eating with central obesity (if uncontrolled), and hypogonadotropic hypogonadism and/or typical behavior problems (including temper tantrums and obsessive-compulsive features). Thus, we propose a lower threshold to prompt diagnostic DNA testing, leading to a higher likelihood of diagnosis of this disorder in which anticipatory guidance and intervention can significantly influence outcome.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            The phenotypic spectrum of Schaaf-Yang syndrome – 18 new affected individuals from 14 families

            Purpose Truncating mutations in the maternally imprinted, paternally expressed gene MAGEL2, which is located in the Prader-Willi critical region 15q11-13, have recently been reported to cause Schaaf-Yang syndrome, a Prader-Willi-like disease, manifesting developmental delay/intellectual disability, hypotonia, feeding difficulties, and autism spectrum disorder. The causality of the reported variants in the context of the patients’ phenotypes was questioned, as MAGEL2 whole gene deletions appear to cause little to no clinical phenotype. Methods Here we report a total of 18 new individuals with Schaaf-Yang syndrome from 14 families, including one family with three individuals found to be affected with a truncating variant of MAGEL2, 11 individuals clinically affected, but not tested molecularly, and a presymptomatic fetal sibling with carrying the pathogenic MAGEL2 variant. Results All cases harbor truncating mutations of MAGEL2, and nucleotides c.1990-1996 arise as a mutational hotspot, with 10 individuals and one fetus harboring a c.1996dupC (p.Q666fs) mutation and two fetuses harboring a c.1996delC (p.Q666fs). The phenotypic spectrum of Schaaf-Yang syndrome ranges from fetal akinesia to individuals with neurobehavioral disease and contractures of the small finger joints. Conclusion This study provides strong evidence for the pathogenicity of truncating mutations of the paternal allele of MAGEL2, refines the associated clinical phenotypes, and highlights implications for genetic counseling of affected families.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Early diagnosis and care is achieved but should be improved in infants with Prader-Willi syndrome

              Background PWS is a severe neurodevelopmental genetic disorder now usually diagnosed in the neonatal period from hypotonia and feeding difficulties. Our study analyzed the birth incidence and care of infants with early diagnosis. Methods Data were collected on 61 infants with a molecular diagnosis of PWS born in 2012 and 2013 in France. Results Thirty-eight infants with PWS were born in 2013. The median age at diagnosis was 18 days. Birth incidence calculated for 2013 was 1/21,000 births. No case was diagnosed prenatally, despite 9 amniocenteses, including 4 for polyhydramnios. Five infants had delayed diagnosis, after 3 months of life. For 2 of them, the diagnosis was not suspected at birth and for 3, FISH analysis in the neonatal period was normal, with no further molecular studies. Ninety-three percent of the neonates were hospitalized, and 84% needed nasogastric tube feeding for a median of 38 days. Swallowing assessment was performed for 45%, at a median age of 10 days. Physiotherapy was started for 76% during hospitalization. Eighty percent of those diagnosed within the first 3 months were seen by a pediatric endocrinologist within the first week of life. Conclusion Our study is the first to assess the birth incidence of PWS in France, at 1/21,000 births. Some prenatal or neonatal cases remain undiagnosed because of unrecognized clinical signs and the inappropriate choice of the initial molecular test. We also underscore the need to optimize neonatal care of infants with PWS.
                Bookmark

                Author and article information

                Contributors
                Christian.Schaaf@uk-koeln.de
                Journal
                Am J Med Genet A
                Am. J. Med. Genet. A
                10.1002/(ISSN)1552-4833
                AJMG
                American Journal of Medical Genetics. Part a
                John Wiley & Sons, Inc. (Hoboken, USA )
                1552-4825
                1552-4833
                10 October 2018
                December 2018
                : 176
                : 12 ( doiID: 10.1002/ajmg.a.v176.12 )
                : 2564-2574
                Affiliations
                [ 1 ] Institute of Human Genetics University Hospital Cologne Köln Germany
                [ 2 ] Department of Pediatrics Baylor College of Medicine Houston Texas
                [ 3 ] Jan and Dan Duncan Neurological Research Institute at Texas Children's Hospital Houston Texas
                [ 4 ] Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas
                [ 5 ] Department of Molecular Physiology and Biophysics Baylor College of Medicine Houston Texas
                [ 6 ] Department of Human Molecular Genetics Max Planck Institute for Molecular Genetics Berlin Germany
                [ 7 ] Department of Clinical Genetics Sydney Children's Hospital Sydney Australia
                [ 8 ] Neuroscience Research Australia (NeuRA) University of New South Wales Sydney Australia
                [ 9 ] Division of Genetics, Birth Defects and Metabolism Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
                [ 10 ] Department of Pediatrics Northwestern University Feinberg School of Medicine Chicago Illinois
                [ 11 ] Division of Medical Genetics and Metabolism Children's Hospital of The King's Daughters Norfolk Virginia
                [ 12 ] Department of Genetics University of Alabama at Birmingham Birmingham Alabama
                [ 13 ] Department of Social Pediatrics Wroclaw Medical University Poland
                [ 14 ] Department of Pediatrics LSU Health Sciences Center and Children's Hospital New Orleans Louisiana
                [ 15 ] Center for Molecular Medicine Cologne University of Cologne Köln Germany
                [ 16 ] Center for Rare Diseases University Hospital Cologne Köln Germany
                Author notes
                [*] [* ] Correspondence

                Christian Schaaf, Institute of Human Genetics, University Hospital Cologne, Kerpener Straße 34, 50931, Köln, Germany.

                Email: Christian.Schaaf@ 123456uk-koeln.de

                Author information
                https://orcid.org/0000-0001-9194-0644
                https://orcid.org/0000-0002-6231-4967
                https://orcid.org/0000-0002-2148-7490
                Article
                AJMGA40650
                10.1002/ajmg.a.40650
                6585857
                30302899
                af598ebd-3fe3-48b6-ab99-85e5e6f5648f
                © 2018 The Authors. American Journal of Medical Genetics Part A published by Wiley Periodicals, Inc.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

                History
                : 01 August 2018
                : 23 August 2018
                : 07 September 2018
                Page count
                Figures: 1, Tables: 3, Pages: 11, Words: 8343
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                ajmga40650
                December 2018
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.4 mode:remove_FC converted:20.06.2019

                Genetics
                autism spectrum disorder,genotype–phenotype association,magel2,neurodevelopment,schaaf‐yang syndrome

                Comments

                Comment on this article